EYPT - Baird sees weakness in Ocular shares overdone in wake of Phase 1 data
2024-04-19 18:07:40 ET
More on Ocular Therapeutix
- Ocular Therapeutix's Impressive Surge: A Strategic Insight
- Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
- Ocular marks early-stage trial win for diabetic retinopathy candidate
- Ocular Therapeutix GAAP EPS of -$0.35 misses by $0.05, revenue of $14.8M misses by $0.91M
- Seeking Alpha’s Quant Rating on Ocular Therapeutix